Comparative Pharmacology
Head-to-head clinical analysis: LANOXIN versus LANOXIN PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANOXIN versus LANOXIN PEDIATRIC.
LANOXIN vs LANOXIN PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside